Orbital raises $270 million in biotech’s largest Series A round this year

Biotechnology venture firms have become more selective about where to invest in recent months, wary of the headwinds currently blowing against the industry.

But that newfound caution hasn’t hurt Orbital Therapeutics, which said Wednesday it raised $270 million in biotech’s largest Series A round this year.